A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

2005692 citationsJournal Article

Authors

Kim Papp · Probity Medical Research

Stephen K. Tyring · The University of Texas Health Science Center at Houston

M. Lahfa · Ludwig-Maximilians-Universität München

Jörg C. Prinz · Probity Medical Research

C.E.M. Griffiths · Ludwig-Maximilians-Universität München

Arline Nakanishi · Hôpital Saint-Louis

Ralph Zitnik

Abstract

Etanercept provided clinically meaningful benefit to patients with chronic plaque psoriasis, with no apparent decrease in efficacy after dose reduction.

Topics & Keywords

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Rheumatoid Arthritis Research and Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Dermatology

Volume 152, Issue 6, pp. 1304-1312

DOI: 10.1111/j.1365-2133.2005.06688.x

Field-Weighted Citation Impact: 13.00